Outset Medical’s (OM) Buy Rating Reiterated at BTIG Research

BTIG Research reissued their buy rating on shares of Outset Medical (NASDAQ:OM) in a report released on Tuesday,Benzinga reports. The firm currently has a $17.00 price objective on the stock.

A number of other equities research analysts have also commented on OM. Royal Bank Of Canada reduced their price objective on shares of Outset Medical from $22.00 to $17.00 and set a “sector perform” rating on the stock in a research note on Tuesday, November 11th. Stifel Nicolaus set a $14.00 target price on Outset Medical and gave the stock a “buy” rating in a research note on Tuesday, November 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of Outset Medical in a research note on Monday, December 8th. Finally, Wall Street Zen raised shares of Outset Medical from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.67.

Outset Medical Trading Down 4.2%

NASDAQ OM opened at $3.61 on Tuesday. The business’s 50-day moving average price is $8.44 and its two-hundred day moving average price is $13.68. The company has a current ratio of 7.09, a quick ratio of 5.77 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $65.52 million, a PE ratio of -0.28 and a beta of 2.03. Outset Medical has a 12 month low of $3.59 and a 12 month high of $25.35.

Institutional Trading of Outset Medical

Several institutional investors have recently made changes to their positions in the company. Legal & General Group Plc purchased a new position in shares of Outset Medical in the 2nd quarter worth approximately $34,000. Ameritas Investment Partners Inc. bought a new position in Outset Medical during the second quarter valued at about $35,000. BNP Paribas Financial Markets increased its holdings in Outset Medical by 7,013.8% during the second quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock worth $40,000 after buying an additional 2,034 shares during the last quarter. Police & Firemen s Retirement System of New Jersey bought a new stake in Outset Medical in the second quarter worth about $78,000. Finally, New York State Common Retirement Fund bought a new stake in shares of Outset Medical in the 2nd quarter worth approximately $108,000.

About Outset Medical

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.